vendredi 6 octobre 2017

Onco Actu du 6 octobre 2017

1. Biologie

2017 Nobel Prize in Chemistry: how making microscopes cool is helping cancer research [Cancer Research UK]

2. Etiologie

Study Identifies Crucial Characteristic of High-Risk HPV [NCI]

2.6 Etiologie - Environnement

EU set to delay vote on weed-killer glyphosate [Reuters]

4.1 Dép., diag. & prono. - Prostate

Strata Oncology, UCSF Partner to Offer $25M in Free Tumor Sequencing [Xconomy]

5.1 Traitements - Pré-clinique

A new CRISPR-engineered cancer model to test therapeutics [Broad Institute]

5.12.2 Immunothérapies - CAR-T

As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing [FiercePharma]

5.12.8 Immunothérapies - Economie

Roche bladder cancer drug struggles as medics focus on survival [Reuters]

5.2.3 Pharma - économie

Eli Lilly defeats challenge to Alimta cancer drug patent [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Most cancer drugs approved by EMA show little benefit: study [PharmaTimes]

Half the cancer drugs approved in Europe recently don’t significantly help patients [STAT]

Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study [Cancer Research UK]

Faster, pricier and often worthless: Study slams regulators for wave of questionable cancer drug OKs [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib) [Lilly]

6.1 Observation

Global burden of disease study focuses on liver cancer [ecancernews]

6.11 Patients

Cancer patients need more than survival [The Guardian]

The Scary Future of Cancer Therapy [HuffPost]

6.5 Médecines alternatives

Complementary and Alternative Medicines and Cancer [Science-Based Medicine]

6.6 Publications

Early data on potential anti-cancer compound now in human trials was falsified, company admits [Retraction Watch]